Purpose: To explore the relationship between regorafenib exposure and efficacy in patients with hepatocellular carcinoma (HCC) who had disease progression during sorafenib treatment (RESORCE). Methods: Exposure-response (ER) analyses for regorafenib were performed using data from a phase 3, randomized, placebo-controlled trial (RESORCE). Patients received 160 mg regorafenib or placebo once daily (3 weeks on/1 week off in a 4-week cycle) with best supportive care until disease progression, death, or unacceptable toxicity. Kaplan-Meier analyses for overall survival (OS) and time-to-progression (TTP) were performed in which regorafenib-treated patients were grouped into four categories according to their estimated average exposure over 4 weeks in cycle 1. While this analysis primarily focused on efficacy, a potential correlation between exposure and treatment-emergent adverse events (TEAEs) was also evaluated. If any differences were observed between Kaplan-Meier plots, the ER analysis continued with a multivariate Cox regression analysis to evaluate the correlation between exposure quartile categories and the efficacy and safety parameters while taking into consideration the effect of the predefined clinically relevant demographic and baseline covariates. The functional form of the ER relationship within the regorafenib treatment group was subsequently evaluated. Results: Based on visual assessment of the Kaplan-Meier plots, no meaningful relationship between the exposure categories and TEAEs were observed, although median OS and TTP tended to be longer in the higher exposure categories. Further ER analyses, which considered the effects of predefined covariates and the different shapes of the ER relationship, focused on efficacy. The baseline risk factors Eastern Cooperative Oncology Group (ECOG) performance status ≥1, alpha-fetoprotein levels ≥400 ng/ml, and aspartate transaminase or alanine transaminase levels > 3 ×upper limit of normal were significantly associated with OS (P < 0.01) and age was associated with TTP. A statistically significant difference was found for OS and TTP between patients receiving regorafenib compared with those receiving placebo in the multivariate ER analysis (P < 0.01) in favor of regorafenib. However, within the group of regorafenib-treated patients, the effect of regorafenib exposure on efficacy, either by estimating four effect sizes for each quartile, or by including a continuous linear or nonlinear relationship between individual exposure and efficacy, was not significant (P > 0.01) and relatively flat. This suggests that increasing regorafenib exposure would not result in a meaningful increase in OS or TTP. Conclusion: After considering the baseline risk factors: ECOG performance status, alpha-fetoprotein levels, and hepatic function for OS and age for TTP, the ER analysis in regorafenib-treated patients showed similar efficacy over the entire predicted exposure range in RESORCE. This supports the selected regorafenib dose of 160 mg once daily (3 weeks on/1 week off in a 4-week cycle) in patients with intermediate or advanced HCC who have experienced disease progression on sorafenib.
Introduction
Regorafenib is an oral multikinase inhibitor approved for patients with treatment-refractory metastatic colorectal cancer and advanced gastrointestinal stromal tumors (Demetri et al., 2013; Grothey et al., 2013; Li et al., 2015; Strumberg et al., 2012) . Regorafenib blocks the activity of protein kinases involved in angiogenesis, oncogenesis, metastasis, and tumor immunity (e.g. vascular endothelial growth factor receptors 1-3, tyrosine kinase with immunoglobulin and epidermal growth factor homology domain 2, platelet-derived growth factor receptor, fibroblast growth factor receptor, and the oncogenic kinases KIT, RET, RAF1, and B-RAF). In preclinical studies, regorafenib has a distinct molecular target profile and more potent pharmacological activity than sorafenib (Abou-Elkacem et al., 2013; Mross et al., 2012; Wilhelm et al., 2011) .
Pharmacokinetic and pharmacodynamic (PKPD) modeling concepts play an important role during drug development, exemplified by the 'Wooden Shoe'paradigm (Breimer and Danhof, 1997) , because they constitute a scientific basis for rational drug discovery and development (Danhof et al., 2005) . Exposure-response (ER) modeling has great potential to improve characterization of the relationship between PK, PD and efficacy/safety in both early and late (confirmatory) studies to support dose selection. ER analyses are valuable in supporting dose selection and optimization for a number of reasons. Firstly, the observed variability in the dose-response relationship (for effectiveness and/or safety) is partly explained by the inter-individual PK differences (e.g. variability in the elimination of a drug). Secondly, the exposure metrics are based on time (e.g. concentration at a specified time) that naturally incorporate the change in concentration and, therefore, response over time (i.e. the time course of onset and duration of the response can be better understood when the dependence of effect on concentration is considered) (Pinheiro and Duffull, 2009) . Therefore, ER relationships provide important information to guide dose selection in subsequent studies, dose optimization in subpopulations, and provide supportive evidence for the effectiveness of a therapeutic product in situations where real-world data are sparse or absent (FDA guidance for industry, 2003) . A recent survey suggested that postmarketing commitments related to dose optimization activities for new molecular entities are common, and that ER analysis showed a potential for increasing the dose to provide additional clinical benefit, providing the safety window permitted doing so (Lu et al., 2016) . Typically, ER analyses consider clinically relevant baseline covariates using logistic regression (models the proportion of new events within a time period) or Cox regression (models the incidence or hazard rate per unit time) to account for potential imbalances of risk factors between exposure groups. Additionally, Wang et al. (2014) described a strategy to evaluate the functional form of the ER relationship, which can be used to guide dose optimization by simulation (Wang et al., 2014) .
Based on promising activity in a second-line phase 2 trial (Bruix et al., 2013) , the phase 3 RESORCE trial (NCT01774344) was conducted to evaluate the efficacy and safety of regorafenib versus placebo in 573 patients with intermediate or advanced HCC who experienced disease progression during sorafenib treatment. Treatment with regorafenib 160 mg once daily (3 weeks on/1 week off in a 4-week cycle) led to improved overall survival (OS) (hazard ratio [HR] 0.63; 95% confidence interval 0.50-0.79; one-sided P < 0.0001), with a median OS of 10.6 months versus 7.8 months with placebo. Improved time-toprogression (TTP) was also observed (HR 0.44; 95% confidence interval 0.36-0.55; one-sided P < 0.0001), with a median TTP of 3.2 months versus 1.5 months with placebo (Bruix et al., 2017) .
The objective of this analysis was to evaluate the relationship between regorafenib exposure and efficacy (OS and TTP) in patients who participated in RESORCE. Analysis of the ER relationship was used to support the regorafenib dose used in RESORCE, by considering the shape of the ER relationship and the possible effects of predefined baseline covariates.
Material and Methods

Study Design and Drug Administration
The phase 3 RESORCE trial was conducted in 21 countries and included adults with HCC Barcelona Clinic Liver Cancer (BCLC) stage B or C (Bruix et al., 2016 and 2017) who received sorafenib ≥400 mg/day for ≥20 days of the last 28 days of treatment, had documented radiological progression on sorafenib, and Child-Pugh A liver function. Patients were randomized 2:1 (stratification by geographic region [Asia vs rest of the world], Eastern Cooperative Oncology Group [ECOG] performance status, alpha-fetoprotein level, extrahepatic spread, and macrovascular invasion) to regorafenib 160 mg (n = 379) or to placebo (n = 194) once daily during Weeks 1-3 of each 4-week cycle. All patients received best supportive care. Treatment continued until disease progression, death, or unacceptable toxicity (Bruix et al., 2017) . The protocol was approved by the ethics committee or institutional review board of each participating institution and complied with the Declaration of Helsinki, current Good Clinical Practice guidelines, and applicable local laws and regulations. All participants voluntarily provided informed consent.
Exposure Parameters
Individual-specific regorafenib clearance was estimated based on sparse PK sampling in cycles 1 and 2 using a previously developed population PK model (Trnkova et al., 2013) combined with the individual dosing histories, to calculate the average regorafenib exposure over 1 cycle of 28 days (CAVD28). CAVD28 was selected as the primary exposure metric because more dosing history information was available for cycle 1 than for cycle 2. Moreover, CAVD28 showed higher between-patient variability compared with the average concentration on Day 1, due to regorafenib PK not reaching steady-state after the first dose and clearance being the only source of variability in the calculation of individual exposure.
Exposure-response Analysis
The possible trend for a univariate correlation between exposure and efficacy (OS and TTP) was evaluated by Kaplan-Meier analyses. Regorafenib-treated patients were stratified into four exposure categories according to their estimated average exposure over cycle 1 (CAVD28). While this analysis primarily focused on efficacy, the univariate correlation between exposure and safety event rates (treatmentemergent adverse events [TEAEs] ) was also evaluated with the aim of exploring if patients with higher regorafenib exposure could be at higher risk of TEAEs. A relevant TEAE was defined as an event related to hypertension, mucositis, rash, asthenia/fatigue, diarrhea, hand-foot syndrome, hemorrhage, hepatic encephalopathy, or liver failure occurring or worsening after start of study drug administration until 30 days after the last dose.
If following visual assessment, the Kaplan-Meier plots stratified by CAVD28 quartiles were separated, the ER analysis continued using a multivariate Cox regression analysis to evaluate the correlation between exposure quartile categories and the efficacy and safety parameters while taking into consideration the effect of the following clinically relevant demographic and baseline covariates:
• Sex (male/female) • Age (< 65/≥65 years) • Serum albumin (< 2.8/2.8 -3.5/ > 3.5 g/dl)
• Child-Pugh scores (A-5/A-6/B-7)
• Hepatitis B, hepatitis C, and alcohol (yes/no) • ECOG performance status (0/≥ 1) • Extrahepatic disease and macrovascular invasion (present/absent)
The distribution of baseline covariates for OS is provided in Supplementary Table S1 ; a similar distribution was observed for TTP.
Placebo data were included to estimate the influence of the demographic and baseline covariates on the probability of safety (TEAEs) or efficacy events, which were assumed to be independent of the treatment received. Due to missing PK sampling or protocol deviations, as well as incomplete dosing histories in cycle 1, not all data from regorafenibtreated patients could be used in the ER analysis. To help minimize the influence of imbalances between the regorafenib and placebo groups, patients were selected for the ER analysis if they: (1) received either regorafenib or placebo; (2) had regorafenib PK samples and complete dosing histories available for cycle 1; (3) had no event/censoring related to OS or TTP in cycle 1; and (4) had no missing categorical baseline covariate information (see Section 3 for the number of patients included in the ER analysis). As criterion (2) was only applicable to regorafenib-treated patients, criterion (3) was defined to help compensate any impact of criterion (2) between the two treatment groups.
Initially, average cycle 1 exposure quartile categories and all baseline covariates were included into a 'full model'. Backward elimination analysis of the 'full model' was performed by removing variables in a stepwise manner until no further variable could be removed, based on the Akaike Information Criteria (measure of model quality). The remaining covariates were tested for statistical significance using the likelihood ratio test and non-significant variables (P > 0.01) were removed from the model, resulting in the 'reduced model'. Patients with missing categorical covariates were excluded from the multivariate analysis; however, patients with missing continuous demographic covariates were imputed as the median of the covariate, stratified by sex and geographical region. Subsequently, the functional form of the ER relationship was assessed using the 'reduced model', replacing the exposure quartiles with the individual continuous exposure. Linear and nonlinear exposure effects on the HR were tested taking into consideration only regorafenib-treated patients, as described by Wang et al. (2014) . Penalized splines (P-splines) were used to evaluate the nonlinear ER relationship (Govindarajulu et al., 2009 ).
Data Analysis
Kaplan-Meier and the Cox regression analyses were conducted using R (The R Foundation for Statistical Computing, version 3.3.0) using the packages 'MASS' (Venables and Ripley, 2002) , 'survival' (Therneau, 2015) , and 'pspline' (Ramsey and Ripley, 2015) .
Results and Discussion
Among the 573 patients randomized to RESORCE, 514 (90%) patients (327 on regorafenib and 187 on placebo) and 488 (85%) patients (315 on regorafenib and 173 on placebo) were included in the ER analysis for OS and TTP, respectively.
Exposure-response Analysis
Kaplan-Meier analysis for efficacy (OS and TTP) and safety (TEAEs) was performed, with regorafenib-treated patients stratified according to the quartile for the selected exposure metric CAVD28. Based on visual assessment, no meaningful relationships between the exposure categories and TEAEs were observed (unpublished data), whereas median OS and TTP tended to be longer in the higher exposure categories and all exposure categories were separated from placebo (Fig 1A and B) .
Nonetheless, a trend towards a higher incidence of common terminology criteria for adverse events grade ≥ 3 was observed in the first exposure quartile, which may explain the lower exposure due to more dose reductions compared with the other exposure quartiles (unpublished data).
Overall Survival
Multivariate ER analysis identified three significant baseline risk factors for OS: ECOG performance status, alpha-fetoprotein levels, and hepatic function based on AST or ALT (P < 0.01), with higher HR estimates for ECOG performance status ≥ 1, alpha-fetoprotein levels ≥ 400 ng/ml, and AST or ALT levels > 3 × ULN (Table 1 ). The average exposure over cycle 1 (CAVD28) grouped in exposure quartile for regorafenib was significantly associated with OS (HR estimates for Q1 − Q4 < 1; Table 1 ). By contrast, the difference in HR between exposure quartiles was found to be small and not significant (95% confidence intervals largely overlapped). CAVD28 was selected based on the considerable range of exposure estimates from as many patients as possible; this selection appeared to be justified because a clear linear correlation between the average exposure over cycles 1 and 2 was observed (average regorafenib concentration over 56 days in cycles 1 and 2 [CAVD56]) ( Supplementary Fig. S1 ), and different inferences were noted when using CAVD56 as the exposure metric. However, CAVD28 does not consider the possible influence of the change in PK over time on the probability of an event. Although time-changing exposure has been considered in parametric time-to-event analyses (Holford, 2013) , specifically in situations where exposure was found to significantly influence the probability of an event, the use of this approach is still under-represented in comparison to Cox regression analyses (Lu et al., 2016) .
Considering the regorafenib group only, no statistically significant linear or nonlinear relationship could be identified between continuous individual exposure and OS (P > 0.01), and the relationship appeared to be relatively flat (see Fig. 2A for the simulated probability for an event related to OS after 1 year of treatment). The relationship for concentrations below the 5th or above the 95th exposure percentile is not clear due to the low number of observations in these exposure ranges (~15 patients for both margins), this is also reflected by the large confidence interval. The simulated probability for an event related to OS after 1 year of treatment indicated that the probability decreased by approximately 5% when increasing the exposure from the upper end of the first exposure quartile (CAVD28 = 1460 ng/ml) to the lower end of the fourth exposure quartile (CAVD28 = 2555 ng/ml). Together, these results suggest that increasing regorafenib exposure would not result in a meaningful increase in OS.
Time-to-progression
Multivariate ER analyses identified a significant correlation with age (P < 0.01), with a HR estimate of < 1 for patients ≥ 65 years of age (Supplementary Table S2 ). The average exposure in cycle 1 grouped into exposure quartiles for regorafenib was also significantly associated with TTP (HR estimates for Q1 − Q4 < 1; Supplementary Table S2) .
Similar to the analysis for OS (Section 3.1.1), no statistically significant linear or nonlinear relationships were observed between continuous individual exposure and TTP (see Fig. 2B for the simulated probability for an event related to TTP after 3 months of treatment).
Dose Selection
This exploratory ER analysis provided evidence that the ER relationship for efficacy was not statistically significant and was relatively flat (Fig 2A and B) . Together with the finding that no meaningful relationship between exposure and TEAEs could be identified, the analysis suggests that the selected dosing regimen in RESORCE (160 mg regorafenib once daily 3 weeks on/1 week off in a 4-week cycle) was tolerated and is more efficacious than placebo over the entire predicted exposure range in the RESORCE trial.
Although ER analysis in general has become a useful and key tool to justify the dose for a product label (Lu et al., 2016) , further research is needed with respect to study design, biomarker development and modeling approaches to enable selection of the optimal dose earlier in the drug development process. Thus new methods need to be evaluated to define the optimal (individual) dose (e.g. by exploring the need for therapeutic drug monitoring and to select patients with low drug exposure or dose titration approaches), already during drug development rather than as postmarketing commitments. Systems pharmacology approaches, described recently by Danhof (2016) in the European Journal of Pharmaceutical Sciences, are promising tools that may provide guidance on selecting prognostic (bio)markers for early signals of efficacy and safety, which will eventually correlate to clinical endpoints, based on the fundamental and quantitative understanding of drug action.
Conclusion
While the Kaplan-Meier analysis indicated that OS and TTP improved slightly with increasing regorafenib exposure, the ER analysis in regorafenib-treated patients showed similar efficacy over the entire predicted exposure range in the RESORCE trial after considering the baseline risk factors (ECOG performance status, alpha-fetoprotein levels, and hepatic function for OS and age for TTP).
The ER relationship in regorafenib-treated patients was relatively flat for efficacy and no meaningful relationship between exposure and TEAEs could be identified. This supports the regorafenib dose of 160 mg once daily (3 weeks on/1 week off in a 4-week cycle) to treat patients with intermediate or advanced HCC who have disease progression on sorafenib. Reference category for each covariate is indicated by the hazard ratio estimate of '1'. AFP, alpha-fetoprotein; ALT, alanine transaminase; AST, aspartate transaminase; CAVD28, average regorafenib concentration over the first 28 days in cycle 1; ECOG, Eastern Cooperative Oncology Group; HR, hazard ratio; LLCI, lower limit confidence interval (2.5%); NA, not applicable; Q, quartile; ULCI, upper limit confidence interval (97.5%). 
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